Pharmacogenomics of multigenic diseases: Sex-specific differences in disease and treatment outcome

AAPS PharmSci

Volumn 5, Issue 4, 2003, Pages

  Pinsonneault, Julia ^a   Sadée, Wolfgang ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Candidate genes; Coronary artery disease; Depression; Multigenic disease; Pharmacogenomics; Schizophrenia; Sex differences

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ESTROGEN; FLUOXETINE; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PRAVASTATIN; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DNA POLYMORPHISM; DRUG RESPONSE; ENZYME INHIBITION; ESTROGEN THERAPY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT INFORMATION; PHARMACOGENOMICS; PHENOTYPE; PSYCHOTHERAPY; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SEX CHROMOSOME; SEX DIFFERENCE; TREATMENT OUTCOME; X CHROMOSOMAL INHERITANCE; Y CHROMOSOMAL INHERITANCE; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; GENETICS; PHARMACOGENETICS; SEXUAL DEVELOPMENT; X CHROMOSOME; Y CHROMOSOME;

CHROMOSOMES, HUMAN, X; CHROMOSOMES, HUMAN, Y; CORONARY ARTERIOSCLEROSIS; DEPRESSION; FEMALE; HUMANS; MALE; PHARMACOGENETICS; SCHIZOPHRENIA; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 0346040090     PISSN: 15221060     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps050429     Document Type: Review

References (77)

1. Ono S. Sex Chromosones and Sex-linked Genes. Berlin, Germany, Springer-Verlag; 1967.
2. Skaletsky H, Kuroda-Kawaguchi T, Minx P, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003;423(6942):825-837.
3. Chinnery P, Turnbull D. Mitochondrial DNA mutations in the pathogenesis of human disease. Mol Med Today. 2000;6:425-432.
4. Barrett A, Smith E, Picker M. Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. Eur J Pharmacol. 2002;452:163-173.
5. Mogil J, Wilson S, Chesler E, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A. 2003;100:4867-4872.
6. Anthony M, Berg M. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J Womens Health Gend Based Med. 2002;11:617-629.
7. Schwartz J. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-121.
8. Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet. 1999;65:183-191.
9. Lusis A. Atherosclerosis. Nature. 2000;407:233-241.
10. Massart F, Reginster J, Brandi M. Genetics of menopause diseases. Maturitas. 2001;40:103-116.
11. Bodnar J, Chatterjee A, Castellani L, et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet. 2002;30(1):110-116.
12. Zwarts K, Clee S, Zwinderman A, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61:115-125.
13. Cardiovascular candidate gene polymorphisms. GeneCanvas Web site. Available at: http://genecanvas.idf.inserm.fr/. Accessed August 2002 - August 2003.
14. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New Engl J Med. 2002;347:1916-1923.
15. Wilson M, Grant P, Kain K, Warner D, Wild C. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S-transferase M1. Biomarkers. 2003;8(1):43-50.
16. Olshan A, Li R, Pankow J, et al. Risk of atherosclerosis: interaction of smoking and glutathione S-transferase genes. Epidemiology. 2003;14(3):321-327.
17. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: encyclopedia for genes, proteins and diseases. GeneCards, an academic Web site of Weizmann Institute of Science, Bioinformatics Unit and Genome Center. Available at: http://bioinformatics.weizmann.ac.il/cards. Accessed August 2003.
18. Povey S, Wain H, Bruford E, et al. Approved Symbols. HUGO Gene Nomenclature Committee Web site. Available at: http://www.gene.ucl.ac.uk/nomenclature/. Accessed August 2003.
19. Kyker K, Limacher M. Gender differences in the presentation and symptoms of coronary artery disease. Curr Womens Health Rep. 2002;2:115-119.
20. Lee W, Cheung A, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men. Diabetes Care. 2000;23:962-968.
21. Kingwell B, Medley T, Waddell T, Cole T, Dart A, Jennings G. Large artery stiffness: structural and genetic aspects. Clin Exp Pharmacol Physiol. 2001;28:1040-1043.
22. De Oliveira e Silva E, Kong M, Han Z, et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. Lipid Res. 1999;40:1211-1221.
23. Ordovas J, Cupples L, Corella D, Otvos J, Osgood D, Martinez A, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterioscler Thromb Vasc Biol. 2000;20:1323-1329.
24. Kuivenhoven J, Jukema J, Zwinderman A, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338:86-93.
25. Herrington D, Howard T, Hawkins G, Reboussin D, Xu J, Zheng S, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
26. Anttila S, Kampman O, Illi A, et al. NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. Psychiatr Genet. 2003;13:61-64.
27. Bjelland I, Tell G, Vollset S, Refsum H, Ueland P. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003; 60:618-626.
28. Blakely R. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci. 2001;21:8319-8323.
29. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A. 2002;99(21):13675-13680.
30. Emilien G, Maloteaux J, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999;84:133-156.
31. Harrison P, Owen M. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003;361:417-419.
32. Huang Y, Oquendo M, Friedman J, et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology. 2002;28:163-169.
33. Huber J, Schneeberger C, Tempfer C. Genetic modeling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas. 2002;42:1-12.
34. Ilani T, Ben-Shachar D, Strous R, et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A. 2001;98(2):625-628.
35. Itokawa M, Arai M, Kato S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett. 2003;347:202-204.
36. Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet. 2002;11(19):2243-2249.
37. Joffe H, Cohen L. Estrogen, serotonin and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44:798-811.
38. Jones I, Middle F, McCandless F, Coyle N, Robertson E, Brockington I. Molecular genetic studies of bipolar disorder and puerperal psychosis at two polymorphisms in the estrogen receptor alpha gene (ESR 1). Am J Med Genet. 2000;96:850-853.
39. Millar JK, Wilson-Annan J, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2002;9:1415-1423.
40. Mirnics K, Middleton F, Stanwood G, Lewis D, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001;6 (3):293-301.
41. Ouyang W, Wang Y, Hong C, Tsai S. Estrogen receptor alpha gene polymorphisms in schizophrenia: frequency, age at onset, symptomology and prognosis. Psychiatr Genet. 2001;11:95-98.
42. Rybakowski J, Borkowska A, Czerski P, Dmitrzak-Weglarz M, Hauser J. The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology. 2003;47:115-119.
43. Toulouse A, Rochefort D, Roussel J, Joober R, Rouleau G. Molecular cloning and characterization of human RAI1, a gene associated with schizophrenia. Genomics. 2003;82:162-171.
44. Veenstra-VanderWeele J, Anderson G, Cook E. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol. 2000;410:165-181.
45. Virgos C, Martorell L, Valero J, et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res. 2001;49:65-71.
46. Xie T, Ho S, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999;56:31-38.
47. Yu Y, Chen T, Wang Y, Liou Y, Hong C, Tsai S. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology. 2003;47:137-140.
48. Zill P, Baghai T, Engel R, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet. 2003;120B:85-89.
49. Bray N, Buckland P, Williams N, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet. 2003;73:152-161.
50. Caspi A, Sugden K, Moffitt T, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
51. Wonodi I, Stine O, Mitchell B, Buchanan R, Thaker G. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet. 2003;120B:47-50.
52. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877-892.
53. Angold A, Costello E, Erkanli A, Worthman C. Pubertal changes in hormonal levels and depression in girls. Psychol Med. 1999;29:1043-1053.
54. Quitkin F, Stewart J, McGrath P, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry. 2002;159:1848-1854.
55. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Neuropsychopharmacology. 2002;5:255-275.
56. Kim K, Lim S, Lee S, et al. Serotonin transporter gene and antidepressant response. Neuroreport. 2000;11:215-219.
57. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the serotonin transporter and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
58. Ahokas A, Turtiainen S, Aito M. Sublingual oestrogen treatment of postnatal depression. Lancet. 1998;351:109.
59. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology (Berl). 1999;146:108-110.
60. Ahokas A, Aito M, Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry. 2000;61:166-169.
61. Sichel D, Cohen L, Robertson L, Ruttenberg A, Rosenbaum J. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38:814-818.
62. Schneider L, Small G, Hamilton S, Bystritsky A, Nemeroff C, Meyers B. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97-106.
63. Herrington D. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol. 2003;14 (2):145-150.
64. Carlsson A, Waters N, Carlsson M. Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatry Clin Neurosci. 1999;249:S37-S43.
65. Stevens J. Schizophrenia: reproductive hormones and the brain. Am J Psychiatry. 2002;159:713-719.
66. Grigoriadis S, Seeman M. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry. 2002;47:437-442.
67. Preston N, Orr K, Date R, Nolan L, Castle D. Gender differences in premorbid adjustment of patients with first episode psychosis. Schizophr Res. 2002;55:285-290.
68. Cowell P, Kostianovsky D, Gur R, Turetsky B, Gur R. Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry. 1996;153(6):799-805.
69. Kuppers E, Ivanova T, Karolczak M, Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J Neurocytol. 2000;29(5-6):375-385.
70. Beyer C, Ivanova T, Karolczak M, Kuppers E. Cell type-specificity of nonclassical estrogen signaling in the developing midbrain. J Steroid Biochem Mol Biol. 2002;81(4-5):319-325.
71. Raap D, DonCarlos L, Garcia F, et al. Ovariectomy-induced increases in hypothalamic serotonin-1A receptor function in rats are prevented by estradiol. Neuroendocrinology. 2002;76 (6):348-356.
72. Arranz M, Kerwin R. Neurotransmitter related genes and antipsychotoic response: pharmacogenetics meets psychiatric treatment. Ann Med. 2000;32:128-133.
73. Larsen T, Friis S, Haahr U, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand. 2001;103:323-324.
74. Ichikawa J, Meltzer H. Relationship between dopaminergic and seratonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):90-98.
75. Arranz M, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615-1616.
76. Zhao H, Pfeiffer R, Gail M. Haplotype analysis in population genetics and association studies. Pharmacogenomics. 2003;4:171-178.
77. Garner C, Slatkin M. On selecting markers for association studies: patterns of linkage disequilibrium between two and three diallelic loci. Genet Epidemiol. 2003;24(1):57-67.